CEL-SCI shares are trading higher after the company announced the British National Institute for Health and Care Excellence selected the company's Multikine as a potential new standard of care for head & neck cancer.
Portfolio Pulse from Benzinga Newsdesk
CEL-SCI Corporation's stock is trading higher following the announcement that the British National Institute for Health and Care Excellence (NICE) has selected its drug Multikine as a potential new standard of care for head and neck cancer.
December 04, 2023 | 4:52 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
CEL-SCI Corporation's stock price is expected to experience a positive impact in the short term due to NICE's selection of Multikine as a potential new standard of care for head and neck cancer.
The selection of Multikine by NICE is a significant endorsement of the drug's potential, which can lead to increased investor confidence and a higher demand for CEL-SCI's shares. This news directly impacts the company's product pipeline and future revenue prospects, making it highly relevant and important to investors. The confidence score reflects the positive nature of the news but accounts for the fact that further regulatory and market acceptance is required for long-term success.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100